These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 8474483

  • 1. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stern GM.
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [Abstract] [Full Text] [Related]

  • 2. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients.
    Poewe W, Kleedorfer B, Wagner M, Bösch S, Schelosky L.
    Adv Neurol; 1993 Apr; 60():656-9. PubMed ID: 8420206
    [No Abstract] [Full Text] [Related]

  • 3. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 4. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J.
    Rev Neurol (Paris); 1990 Nov; 146(2):116-22. PubMed ID: 2320817
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
    García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, Arbelo González J, Baiges Octavio J, Burguera Hernández JA, Calopa Garriga M, Campos Blanco D, Castaño García B, Carballo Cordero M, Chacón Peña J, Espino Ibáñez A, Gorospe Onisalde A, Giménez-Roldán S, Granés Ibáñez P, Hernández Vara J, Ibáñez Alonso R, Jiménez Jiménez FJ, Krupinski J, Kulisevsky Bojarsky J, Legarda Ramírez I, Lezcano García E, Martínez-Castrillo JC, Mateo González D, Miquel Rodríguez F, Mir P, Muñoz Fargas E, Obeso Inchausti J, Olivares Romero J, Olivé Plana J, Otermin Vallejo P, Pascual Sedano B, Pérez de Colosía Rama V, Pérez López-Fraile I, Planas Comes A, Puente Periz V, Rodríguez Oroz MC, Sevillano García D, Solís Pérez P, Suárez Muñoz J, Vaamonde Gamo J, Valero Merino C, Valldeoriola Serra F, Velázquez Pérez JM, Yáñez Baña R, Zamarbide Capdepon I.
    Mov Disord; 2008 Jun 15; 23(8):1130-6. PubMed ID: 18442107
    [Abstract] [Full Text] [Related]

  • 6. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov 15; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 7. [Apomorphine test in Parkinson disease--dose and corresponding parameters].
    Pinter MM, Helscher RJ, Sattler AP.
    Wien Klin Wochenschr; 1993 Nov 15; 105(16):472-5. PubMed ID: 8212705
    [Abstract] [Full Text] [Related]

  • 8. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H.
    Acta Neurol Scand; 2009 May 15; 119(5):345-8. PubMed ID: 18822087
    [Abstract] [Full Text] [Related]

  • 9. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb 15; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J, Merims D, Kuritzky A, Ziv I, Melamed E.
    Harefuah; 1999 Nov 15; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Nov 15; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 18. [Sublingual administration of apomorphine in the treatment of motor fluctuations in Parkinson disease].
    Durif F, Deffond D, Eschalier A, Tournilhac M.
    Rev Neurol (Paris); 1992 Nov 15; 148(10):610-4. PubMed ID: 1295055
    [Abstract] [Full Text] [Related]

  • 19. [Apomorphine in Parkinson disease].
    Gilhus NE.
    Tidsskr Nor Laegeforen; 1991 Oct 30; 111(26):3166-9. PubMed ID: 1948940
    [Abstract] [Full Text] [Related]

  • 20. [Apomorphine in the treatment of Parkinson disease].
    Christensen PB, Dupont E, Jensen NB.
    Ugeskr Laeger; 1991 Sep 16; 153(38):2631-4. PubMed ID: 1949272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.